Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

Not Applicable
Conditions
Interventions
First Posted Date
2013-06-07
Last Posted Date
2013-06-07
Lead Sponsor
Huashan Hospital
Target Recruit Count
200
Registration Number
NCT01872858
Locations
🇨🇳

Dept. of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China

The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-06-03
Last Posted Date
2014-07-01
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
32
Registration Number
NCT01867281
Locations
🇮🇷

Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Mildronate for Acute Ischemic Stroke

First Posted Date
2013-04-12
Last Posted Date
2013-04-12
Lead Sponsor
Xijing Hospital
Target Recruit Count
227
Registration Number
NCT01831011
Locations
🇨🇳

the Department of Neurology, Xi an, Shanxi, China

Mediators of Abnormal Reproductive Function in Obesity (MARO)

First Posted Date
2013-03-25
Last Posted Date
2015-03-17
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
10
Registration Number
NCT01817400
Locations
🇺🇸

University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States

Pharmacogenomics of Antiplatelet Response - I

First Posted Date
2013-03-20
Last Posted Date
2017-01-09
Lead Sponsor
Johns Hopkins University
Target Recruit Count
19
Registration Number
NCT01815008
Locations
🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

First Posted Date
2013-03-19
Last Posted Date
2022-03-15
Lead Sponsor
ECRI bv
Target Recruit Count
15991
Registration Number
NCT01813435
Locations
🇧🇪

Research centre Aalst, 3201, Aalst, Belgium

🇧🇪

Research centre Genk, 3205, Genk, Belgium

🇦🇹

Research centre Graz, 4305, Graz, Austria

and more 127 locations

Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty

First Posted Date
2013-03-12
Last Posted Date
2014-04-21
Lead Sponsor
LifeBridge Health
Target Recruit Count
54
Registration Number
NCT01809054
Locations
🇺🇸

Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland, United States

🇺🇸

Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

Edoxaban in Peripheral Arterial Disease

First Posted Date
2013-03-01
Last Posted Date
2019-02-26
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
203
Registration Number
NCT01802775
Locations
🇧🇪

Edgem, Edegem, Belgium

Efficacy and Safety of Mildronate for Acute Ischemic Stroke

First Posted Date
2013-02-27
Last Posted Date
2013-02-27
Lead Sponsor
Xijing Hospital
Target Recruit Count
240
Registration Number
NCT01800357
Locations
🇨🇳

the Department of Neurology , Xijing Hospital, Xi'an, Shaanxi, China

© Copyright 2024. All Rights Reserved by MedPath